BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32089329)

  • 1. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
    Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
    Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure.
    Hartleben C; Parra JC; Batoosingh A; Bernstein P; Goodkin M
    J Ophthalmol; 2017; 2017():4586763. PubMed ID: 29057117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
    Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
    Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.
    Alezzandrini A; Hubatsch D; Alfaro R
    Adv Ther; 2014 Sep; 31(9):975-85. PubMed ID: 25138224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
    Natt NK; Gupta A; Singh G; Singh T
    Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
    Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
    Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension.
    Hommer A;
    Eur J Ophthalmol; 2007; 17(1):53-62. PubMed ID: 17294383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.